David F Fischer on target screening
Drug Target Review editor Steve Bremer asks David F Fischer for his views on target discovery and validation in drug discovery. David F Fischer, PhD, is Executive Director Biology at Charles River...
List view / Grid view
Articles
Using venoms to uncover new targets in drug discovery
A range of drugs used in modern medicine are derived from animal venoms, and Steve Trim from Venomtech discusses how natural selection has made venoms particularly useful tools for uncovering new targets in drug discovery...
New drug targets identified to defend against chlamydia infections using CRISPR and stem cells
Human induced pluripotent stem cell derived macrophages (iPSDMs) provide a cell-based model system to study chlamydia infection in the laboratory. Amy Yeung from Wellcome Trust Sanger Institute explains how she used this model in combination with CRISPR-Cas 9 technology to explore the potential of the two genes, IRF5 and IL10RA,…
Intracellular target validation in cellular systems … using peptides!
Paul Grant from Venomtech suggests that because animal venoms contain proteins and peptides that disrupt cell membrane integrity, they offer a new approach to drug discovery...
Q&A: The role of disease focused foundations in bridging the drug discovery and development gap
Bio 2017 opens this week and Drug Target Review’s Niamh Marriott spoke with Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec and Salvatore La Rosa, Vice President Research and Development, Children’s Tumor Foundation, to get their perspectives on one of the event’s most pressing trends. Both will be…
Plant-Mediated Modulation of Reactive Oxygen Species (ROS) Homeostasis
A review of Keap1/Nrf2 modulation of ROS homeostasis, and its pivotal role in the pathogenesis of cancer, Type 2 diabetes mellitus & neurological disorders.
Targets In-Depth Focus 2017
Included in this Targets In-Depth Focus: Intracellular target validation in cellular systems; New drug targets identified to defend against chlamydia infections using CRISPR and stem cells; Novel solutions for tough targets with real bite...
Stem Cells In-Depth Focus 2017
Included in this Stem Cells In-Depth Focus: Translating discoveries into therapies; The key to successful manufacturing of patient-specific cell therapies; Interview with Alessandro Prigione and James Adjaye...
Screening In-Depth Focus 2017
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
Insights from discovery through clinical efficacy to support a new class of therapeutics in Alzheimer’s disease
Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013.
Using native mass spectrometry to inform drug discovery
Mass spectrometry (MS) performed under native-like conditions (nMS) is a promising approach for studying protein-drug interactions, and has already informed treatments of some of the most intractable diseases including cancer, diabetes and Alzheimer’s.
Review: Biomarkers towards personalised therapy in cancer
Since the sequence of the human genome was published some 20 years ago, omics strategies have enabled the generation of detailed molecular signatures of cancers and their subtypes.
Drug Target Review – Issue #2 2017
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer's disease...
3D bioprinting – from science fiction to reality?
The global 3D bioprinting market is predicted to reach $1.8 billion in revenue by 2027. IDTechEx's Dr Nadia Tsao explains why...
Creating the ‘google earth’ of tumours
We caught up with Dr Josephine Bunch to find out how NPL are using the Cancer Research Grand Challenge funding & novel imaging techniques to map cancer tumours...
